The US Food and Drug Administration (FDA) has granted 510(k) clearance to NovaBay Pharmaceuticals' NeutroPhase skin and wound cleanser for use in moistening and debriding graft and donor sites. The approval allows the company to use ...
Tags: FDA, wound cleanser, clinical application
NovaBay Pharmaceuticals has received a $1.5m equity investment from Pioneer Pharma. With the investment, Pioneer has completed $2.5m investment of total $5.5m. The investment forms part of the expansion of the NeutroPhase distribution ...